{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:24:11Z","timestamp":1718929451542},"reference-count":0,"publisher":"MJH Life Sciences","issue":"3806","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,5]]},"abstract":"<jats:p>The June Hot Topics focuses on the challenges venetoclax regimens have faced in multiple myeloma trials.<\/jats:p>","DOI":"10.46883\/2024.25921023","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T13:47:22Z","timestamp":1718891242000},"page":"239-241","source":"Crossref","is-referenced-by-count":0,"title":["Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials"],"prefix":"10.46883","member":"25947","published-online":{"date-parts":[[2024,6,14]]},"container-title":["ONCOLOGY"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T13:47:23Z","timestamp":1718891243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cancernetwork.com\/view\/continued-success-of-venetoclax-in-t-11-14-multiple-myeloma-despite-negative-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":0,"journal-issue":{"issue":"3806","published-online":{"date-parts":[[2024,6,11]]},"published-print":{"date-parts":[[2024,6,5]]}},"URL":"https:\/\/doi.org\/10.46883\/2024.25921023","relation":{},"ISSN":["0890-9091"],"issn-type":[{"value":"0890-9091","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,5]]}}}